Akums Drugs and Pharmaceuticals Limited — Q1 FY26
Akums Drugs reported a mixed Q1 FY26.
neutral
medium
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
68%Questions answered3Evaded / deflected11Questions auditedContradictedNumbers vs filing
Evasive
High priority
Revenue potential from first EU P2 approval and R&D technology adoption.
Asked by Rahan Sayyad, Three Asset Managers
Management declined to provide a specific revenue estimate, instead describing the pipeline broadly.
no number givenreframed to pipeline description
Read the exchange
Question
So you have mentioned receiving the first P2 approval for rework X7 and filing a W combination in Swan. So could you share the specific revenue potential from this launch over the next three years?
Management (unidentified)
I cannot really put down a number of what will be the overall size but river oxaban which is alo is a large molecule globally right so we expect it to continue...
Partial answer
High priority
Full-year growth guidance for CDMO business and API pricing trends.
Asked by Vive Agarwal, City Group
Management revised growth from mid-to-high single digit to mid single digit but did not quantify volume growth.
revised guidance downwardno specific volume growth number
Read the exchange
Question
the growth was again muted around 4 5% kind of thing so how to look at uh fular growth in this particular segment and uh what are the trends as far as the API pricing is concerned
Management (unidentified)
the guidance which we initially gave was a mid to high singledigit growth in the top line in the CDMO business. Right? what we observed in the Q1 was a 2 and a half% decline in our API pricing... we would target a mid single digit growth as of now
Evasive
Medium priority
Reason for margin dip from 15.5% to 14.7%.
Asked by Vive Agarwal, City Group
Management dismissed the margin decline as a quarterly blip without explaining the cause.
attributed to quarterly blipno specific reason given
Read the exchange
Question
we also seen a marginally dip as far as the margins are concerned right 15.5 to around 14.7% so what has led to this
Management (unidentified)
I think this is quarterly blip as we also mentioned earlier this business is really looked at at an annual level. So a 14 to 15% margin is what we usually deliver in this business.
Answered
Medium priority
Impact of lower API prices on CDMO margin percentage.
Asked by Madha, Fidelity
Management directly explained that margins are cost-plus and fixed percentage, so lower API prices don't change margin percentage.
Read the exchange
Question
if API prices are lower shouldn't the percent margins for us start moving higher just mathematically is that the right way to think about the margin profile
Management (unidentified)
the margins that we get in this business are a cost plus on a percent basis right so for example if on a certain doses form I make a 15% margin that 15% stays right
Answered
Medium priority
Revenue capture location for export CDMO vs international branded.
Asked by Madha, Fidelity
Management clearly distinguished that international branded is a separate segment, while export CDMO is within CDMO.
Read the exchange
Question
when you have given international branded formulation of 35 cr that's basically the export CDMO business or the export CDMO business is captured in the CDMO segment itself right where does our revenue capture today export
Management (unidentified)
CDMO is anything we do in India or exports so so the international branded is what we classify as a segment so branded is our brands correct
Answered
High priority
Business model and competitive advantage in Europe.
Asked by Madha, Fidelity
Management outlined three levers for European market entry, addressing the business model question.
Read the exchange
Question
could you give some more sense around the business potential in Europe and basically could you explain a little bit about the business model as well
Management (unidentified)
our first lever is it is CDMO what we'll do as a group largely in the European market... second is focusing on products and molecules where there is limited competitive intensity... third is tapping clients not just in India but outside as well
Answered
Medium priority
Plans for generic semaglutide and injectable fill-finish.
Asked by Madha, Fidelity
Management clearly stated semaglutide is not a priority and explained why.
Read the exchange
Question
when generic versions of this product get launched next year are we planning to be in this product at all or we will not focus on this product?
Management (unidentified)
this is not a core segment for us... most of the Indian formulation players are doing it in-house only. So the total addressable market for a CDMO gets squeezed down.
Evasive
Low priority
Share of anti-diabetes therapy in domestic CDMO business.
Asked by Madha, Fidelity
Management did not provide the requested breakdown, citing system limitations.
no specific number givendeferred to IPO data
Read the exchange
Question
in the domestic cmo business which we have of like 3200 crores last year uh how much of this was anti-diabetes uh therapy for us
Management (unidentified)
in our SAP we tag brands and not even molecules right so then it has to be tagged to therapy. So while we don't do it what we did during our IPO times I can probably share that this completely reflects the IPM only.
Answered
High priority
Pricing model and margins for European market.
Asked by Hersh Bharta, Bandan AMC
Management explained that European pricing is largely fixed, not cost-plus, and margins will be better than domestic CDMO.
Read the exchange
Question
how would the pricing be decided... will it broadly be a cost plus model that we follow in 3D market plus how would the margins for the European market.
Management (unidentified)
Europe what we have realized honestly is cost plus is a limited part of the model model largely it is a fixed pricing whether it's a private market or a tender market
Evasive
Medium priority
Full-year growth outlook for domestic branded formulations.
Asked by Vive Agarwal, City Group
Management did not quantify expected growth, only said it should track IPM.
no specific growth numberattributed to one quarter blip
Read the exchange
Question
In the domestic business, how to look what for the fullear growth given that we have seen a subdued growth in this particular quarter
Management (unidentified)
domestic branded formulations should track the IPM growth... we see the growth coming back in due to the rest of the year. So we should be tracking the IPL.
Answered
High priority
Annual revenue run rate from EU CDMO contract starting April 2027.
Asked by Madha, Fidelity
Management provided a specific revenue figure of at least 300 crores annually.
Read the exchange
Question
could you give some sense? It's basically FI 28. How much could be the annual revenue run rate from this contract for us
Management (unidentified)
we should do at least 300 crores annually from this contract. and yes April 27 is when we start commercial supplies.
Answered
High priority
Five-year export revenue aspiration including EU contract.
Asked by Madha, Fidelity
Management gave a specific target of $100 million in exports over five years.
Read the exchange
Question
how big can this opportunity be for us in the next let's say two or three years time... from exports how much should we do?
Management (unidentified)
over the five years time we should target maybe $100 million in exports.
Quantitative claims vs filed numbers
| Claim | Management said | Filing | Verdict |
|---|---|---|---|
| EU CDMO contract annual revenue at least 300 cr | ₹300 cr | ₹1,024 cr | Understated vs filing |
| Five-year export target $100 million | 100 | 1,024 | Understated vs filing |
Filed figures sourced from Screener.in. Claims within a small tolerance of the filing are marked “matches filing”.